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Abstract 
 
Rationale: Most cognitive domains show only minimal improvement following typical or atypical 
antipsychotic treatments in schizophrenia, and some may even worsen. One domain that may worsen 
is procedural learning, an implicit memory function relying mainly on the integrity of the fronto-
striatal system.  
Objectives: We investigated whether switching to atypical antipsychotics would improve procedural 
learning and task-related neural activation in patients on typical antipsychotics. Furthermore, we 
explored differential effects of the atypical antipsychotics risperidone and olanzapine.  
Methods: Thirty schizophrenia patients underwent functional magnetic resonance imaging during a 5-
min procedural (sequence) learning task on two occasions: at baseline and 7-8 weeks later. Of 30 
patients, 10 remained on typical antipsychotics and 20 were switched randomly in equal numbers to 
receive either olanzapine (10-20 mg) or risperidone (4-8 mg) for 7-8 weeks.  
Results: At baseline, patients (all on typicals) showed no procedural learning. At follow-up, patients 
who remained on typical antipsychotics continued to show a lack of procedural learning whereas 
those switched to atypical antipsychotics displayed significant procedural learning (p=0.001), and 
increased activation in the superior-middle frontal gyrus, anterior cingulate and striatum (cluster-
corrected p<0.05). These neural effects were present as a linear increase over five successive 30-s 
blocks of sequenced trials. A switch to either risperidone or olanzapine resulted in comparable 
performance but with both overlapping and distinct task-related activations.   
Conclusions: Atypical antipsychotics restore procedural learning deficits and associated neural 
activity in schizophrenia. Furthermore, different atypical antipsychotics produce idiosyncratic task-
related neural activations and this specificity may contribute to their differential long-term clinical 
profiles.  
 
 
Keywords: Sequence learning. Striatum. Anterior cingulate. Typical antipsychotics. Atypical 
antipsychotics 
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Introduction 
Schizophrenia is a complex neurobiological disorder thought to arise from a dysregulation of multiple 
neurotransmitters including the dopaminergic, glutamatergic and serotonergic systems (Coyle 2006; 
Davis et al. 1991; Geyer and Vollenweider 2008; Howes and Kapur 2009; Javitt and Zukin 1991; van 
Rossum 1966). In addition to the core symptoms that form the diagnostic criteria, cognitive 
impairment has been increasingly described as a prominent feature of schizophrenia that should be a 
target for treatment (Carter and Barch 2007), given its relationship with poor functional outcome and 
no established treatment so far (Harvey and Bowie 2012). 
Existing pharmacological treatments include typical antipsychotics and, more recently, 
atypical antipsychotics. Typical antipsychotics, such as fluphenazine, haloperidol and chlorpromazine, 
may alleviate psychotic symptoms through blockade of dopamine D2 receptors in the striatum (Abi-
Dargham 2004; Laruelle and Abi-Dargham 1999; Peroutka and Synder 1980). Commonly prescribed 
atypical antipsychotics such as risperidone and olanzapine act on multiple neurotransmitter systems 
(Kapur et al. 1998; Nord and Farde 2011). Risperidone has high affinity for both serotonin 2A receptor 
(5-HT2A) and dopamine D2 receptors and modest affinity for histamine and alpha-2 (α2) adrenergic 
receptors (Leysen et al. 1994). Olanzapine has high affinity for 5-HT2A and moderate affinity for D2, 
muscarinic M 1-4, α 1-2, and histamine H1 receptors (Arnt and Skarsfeldt 1998). Furthermore, most 
atypical antipsychotics occupy D2 receptors only transiently, and dissociate rapidly to allow normal 
dopamine neurotransmission (Seeman 2002). 
Although antipsychotics were synthesised primarily to attenuate psychotic symptoms, their 
clinical benefits and/or side effects may extend to cognitive performance, and this needs to be 
examined with specific cognitive paradigms on both the behavioural and the neural level (Honey and 
Bullmore 2004). The use of atypical antipsychotics has been reported to alleviate cognitive 
impairment, at least to some degree (Woodward et al. 2005), though studies comparing the effects of 
typical and atypical studies have been less conclusive (Carpenter and Conley 2007; Green et al. 2002; 
Keefe et al. 2007b; Meltzer 2004). While it is desirable that patients demonstrate generalised 
cognitive improvement, there is also a need to find out whether any of the specific cognitive deficits, 
result from, or become exaggerated by, antipsychotic treatments (Heinrichs 2007; Hill et al. 2010).  
Due to the multi-factorial nature of most traditional neuropsychological tests, they offer 
limited sensitivity to specific cognitive changes induced by antipsychotics (Carter and Barch 2007). 
Procedural learning (PL), which refers to the gradual acquisition of skills through repeated exposure 
of a specific rule-governed activity (Cohen and Squire 1980), may provide a useful measure in this 
context. There is consistent evidence that PL is sensitive to dopaminergic changes, particularly in the 
striatum (Foerde and Shohamy 2011). Functional integrity of the striatum has been shown to be 
critical for PL particularly when assessed using the serial reaction time task (SRTT) or one of its 
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variants (Doyon et al. 1998; Knopman and Nissen 1991; Nissen and Bullemer 1987; Rauch et al. 
1997). SRTT is a visuospatial tracking task in which participants gradually acquire the pattern of 
repeating sequences amongst embedded random blocks without developing explicit awareness of their 
learning (Howard and Howard 1997). The learning of sequences results in faster reaction time (RT) 
for the sequence trials compared to the random trials, reflecting PL. 
A meta-analysis revealed a moderate degree of impairment in PL on the SRTT in patients 
with schizophrenia relative to controls with a pooled effect size of 0.51 (Siegert et al. 2008). The 
studies, however, varied in medication and patient characteristics. The potential influence of 
antipsychotics on SRTT performance is indicated by healthy volunteer studies where otherwise 
normal performance is compromised by acute administration of haloperidol (Kumari et al. 1997) and 
chlorpromazine (Danion et al. 1992) but enhanced by the indirect dopamine agonist d-amphetamine 
(Kumari et al. 1997). Absence of PL on the SRTT has been observed in patients on typical 
antipsychotics (Kumari et al. 2002) but not when they are on atypical antipsychotics (Kumari et al. 
2008; Stevens et al. 2002). Medication-naïve first-episode patients, and recent onset patients with 
minimal prior exposure to antipsychotics, show lower learning profiles and larger inter-trial 
fluctuations, but no robust impairment in SRTT performance (Kumari et al. 2008; Purdon et al. 2011).  
Parallel to these behavioural findings, there is evidence from a single-photon emission 
computed tomography (SPECT) study that PL deficits induced by haloperidol may be 
dopaminergically mediated in the striatum (Paquet et al. 2004). Functional magnetic resonance 
imaging (fMRI) studies implementing variants of the SRTT have repeatedly shown aberrant fronto-
striatal activations in schizophrenia, relative to healthy, groups (Kumari et al. 2008; Kumari et al. 
2002; Purdon et al. 2011; Reiss et al. 2006; Zedkova et al. 2006). Patients on typical antipsychotics 
show fronto-striatal activation deficits (Kumari et al. 2002) whereas those on ziprasidone (Kumari et 
al. 2008) and unmedicated first episode patients show activation patterns broadly similar to that of 
healthy controls (Purdon et al. 2011). It is thus likely that the use of typical antipsychotics gives rise 
to commonly observed PL deficits, possibly in addition to an underlying neural abnormality affecting 
many cognitive functions, in schizophrenia. No study has yet investigated the neural changes 
accompanying the effects of switching from typical to atypical antipsychotics in PL on the SRRT in 
schizophrenia patients. Investigating changes following a switch from typical to atypical treatment 
can not only clarify the impact of typical and atypical antipsychotic treatment on PL but also provide 
new insights into the differential neural effects of atypical antipsychotics.  
The primary aim of this study was to apply fMRI in a longitudinal within-subjects design 
(pre- and post) to detect changes in the blood-oxygen-level-dependent (BOLD) response during a PL 
task (SRTT) following a switch to one of two atypical antipsychotics, risperidone and olanzapine, in 
patients previously on stable does of typical antipsychotics. Risperidone and olanzapine were chosen 
over other atypical antipsychotics because they, despite both being classified as atypical 
antipsychotics, have relatively distinct pharmacological profiles (Arnt and Skarsfeldt 1998; Leysen et 
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al. 1994; Miyamoto et al. 2008) and are also two of the most commonly prescribed antipsychotics to 
people with schizophrenia. We hypothesised that the substitution of atypical for typical antipsychotics 
would be associated with improved PL and restored activation of neural systems that subserve PL in 
healthy people. In addition, considering the different receptor profiles of atypical antipsychotics 
(Miyamoto et al. 2008), possible differences in PL and associated neural patterns between olanzapine 
and risperidone were explored.  
 
Method  
Participants and design 
Thirty patients (aged 18-61 years) with a DSM-IV (Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition) diagnosis (First et al. 1996) of schizophrenia participated. All included patients 
were required to be i) on stable doses of typical antipsychotics for 6 or more weeks, ii) free from illicit 
drugs (confirmed with urine analysis), iii) strongly right-handed as determined using the Edinburgh 
Handedness Inventory (Oldfield 1971), and (iv) able to provide written informed consent. Patients 
entering the study were examined clinically to ensure compliance with the inclusion and exclusion 
criteria.  
The study was a single-centre, open label study, with blinded ratings. Within 1 week of 
baseline assessment, out of 30 patients recruited into the study, 10 were randomised to remain on 
typical antipsychotics for the duration of this study while 20 patients were randomly allocated to 
receive treatment with atypical antipsychotics olanzapine (n=10) or risperidone (n=10). The person 
responsible for randomisation was aware of patients’ gender and age but unaware of the results of 
baseline clinical and neuroimaging results. Starting doses for atypical antipsychotics were according 
to the “Summary of Product Characteristics” for each of the two drugs: 10 mg for olanzapine and 2 
mg for risperidone. Optimal dose was achieved within 14 days and patients were re-assessed after 
having been on the optimal dose for 6 weeks. The optimal dose range for riseridone was 4-8 mg and 
for olanzapine 10-20 mg. All participants underwent fMRI during the PL task on two occasions: at 
baseline and then again 7-8 weeks later. Severity of symptoms was rated with the Positive and 
Negative Syndrome Scale (PANSS) (Kay et al. 1987) on both occasions. Predicted IQ was assessed 
using the National Adult Reading test (NART) (Nelson and Willison 1991) at baseline for sample 
characterisation. The age of onset of illness and the type and doses of current antipsychotic treatment 
were also recorded. Data were unusable due to motion artefacts or image acquisition failures at 
baseline or follow-up for one patient of each of the risperidone and olanzapine groups, and two 
patients of the typical group. In addition, one patient of the risperidone group did not provide 
behavioural data (failed to press the button on most trials) during fMRI and one patient of each of the 
olanzapine and risperidone groups did not attend their follow-up scan. The final sample thus 
comprised 23 patients: 8 on typical (at baseline 3 on flupenthixol decanoate, 4 zuclopenthixol 
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decanoate and 1 on fluphenazine decanoate) and 15 on atypical antipsychotics [7 risperidone (at 
baseline 2 on flupenthixol decanoate, 3 zuclopenthixol decanoate, 1 fluphenazine decanoate and 1 on 
trifluoperazine), 8 olanzapine (at baseline 3 on flupenthixol decanoate, 2 zuclopenthixol decanoate, 2 
fluphenazine decanoate and 1 on sulpiride)] (Table 1). 
 
****Table 1 about here**** 
 
The study procedures were approved by the ethics committee of the Institute of Psychiatry 
and Maudsley Hospital, London. Participants provided written informed consent after the methods 
and procedure had been discussed with them.  
 
Experimental design and procedure 
This study used the same PL task, i.e. a five-minute sequence learning task in a blocked periodic AB 
design, as used in a number of previous studies (Ettinger et al. 2013; Kumari et al. 2008; Kumari et al. 
2002). Briefly stated, the task consisted of two 30-s alternating conditions: blocks of random trials 
(control condition) and blocks of pattern trials (experimental condition). In total, there were five 30-s 
random and five 30-s pattern conditions. Participants were presented with a white target stimulus (an 
asterisk) projected on to a black screen via a prismatic mirror fitted in the radiofrequency head coil as 
they lay in the scanner. The screen was divided into four equal quadrants by two intersecting white 
lines, and the target moved between these four locations on the screen.  
 For the pattern condition, the target movements were predictable for 75% of cases, i.e. 
stimulus locations were determined following three specific rules: (1) a horizontal target movement 
was followed by a vertical target movement; (2) a vertical target movement was followed by a 
diagonal target movement; (3) a diagonal target movement was followed by a horizontal movement. 
The fourth movement of the target during the pattern condition was determined randomly, which then 
was followed by the abovementioned three specific rules.  
Participants were required to follow each target movement with their right hand as fast as 
possible using a MRI compatible key pad with four keys, each key corresponding to one of the four 
quadrants. The movement of the target was initiated by the participants’ touching the target key. RTs 
were recorded on-line. Participants were not told about the predetermined sequence during the pattern 
condition, and the beginning of random and pattern condition was not marked in any way. Prior to 
scanning, all participants underwent a practice session during which they practiced on five 30-s 
random and five 30-s pattern condition, both alternated with 30-s rest periods. 
 
Image acquisition 
Echoplanar MR brain images were acquired using a 1.5 T GE Signa system (General Electric, 
Milwaukee, WI, USA) at the Maudsley Hospital, London. Daily quality assurance was carried out to 
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ensure high signal-to-ghost ratio, high signal-to-noise ratio and excellent temporal stability using an 
automated quality control procedure (Simmons et al. 1999). A quadrature birdcage head coil was used 
for radio frequency transmission and reception. In each of 16 near-axial, non-contiguous planes 
parallel to the intercommissural (AC-PC) plane, 100 T2*-weighted MR images depicting blood 
oxygenation level-dependent (BOLD) contrast (Ogawa et al. 1990) were acquired over the 5 minute 
experiment with echo time (TE) = 40 ms, repetition time (TR) = 3 s, in-plane resolution = 3.1 mm, 
slice thickness = 7.0 mm, and interslice gap = 0.7 mm. Head movement was limited by foam padding 
within the head coil and a restraining band across the forehead. At the same session, a high-resolution 
3-D inversion recovery prepared spoiled GRASS pulse sequence was used to acquire a T1-weighted 
volume in the axial plane (TR=12.2 ms, TE=5.3 ms, TI=300 ms, flip angle=20o, in-plane 
resolution=0.94 mm, matrix dimensions 256 x 256), yielding 124 contiguous slices of 1.5 mm 
thickness. 
 
Data analysis 
All demographic, clinical and behavioural measures were analysed using SPSS version 22.00 (SPSS 
Inc., Chicago, IL USA). Effect sizes, where reported, are partial eta squared (i.e., the proportion of 
variance associated with a factor). The α-level of significance (two-tailed) was set at p < 0.05 unless 
indicated otherwise.  
 
Demographic and clinical measures 
Typical and atypical antipsychotic groups were compared on age, education and predicted IQ using a 
one-way analysis of variance (ANOVA). The data on positive symptoms, negative symptoms, general 
psychopathology and total PANSS scores were analysed (separately)  with a 2 (typical, atypical) x 2 
(baseline, follow-up) repeated measures ANOVA.   Further one-way ANOVAs were conducted to 
compare the two atypical antipsychotic subgroups (risperidone, olanazapine) on age, education and 
predicted IQ, and 2 (risperidone, olanzapine) x 2 (baseline, follow-up) repeated measures ANOVAs to 
examine changes in  positive symptoms, negative symptoms, general psychopathology and total 
PANSS scores.  
 
Task performance 
To examine group differences at baseline and follow-up, mean RTs to blocks of random and pattern 
trials at baseline and follow-up were subjected to a four-way Group (2: typical, atypical) x Occasion 
(2: baseline, follow-up) x Trial type (2: random, pattern) x Block (5: five 30-s blocks of random and 
pattern trials) ANOVA with Group as a between-subjects factor, and Occasion, Trial Type and Block 
as within-subjects factors, followed by lower order ANOVAs and post-hoc mean comparisons as 
appropriate. A further Group (risperidone, olanzapine) x Occasion x Trial type x Block ANOVA was 
carried out to explore possible differences between different atypical antipsychotics, followed by 
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lower order ANOVAs and post-hoc mean comparisons. Finally, we examined potential associations, 
across patients, between age, illness duration and symptom levels and PL scores at baseline and 
follow-up using Pearson’s correlations.  
 
fMRI 
Data were analysed using statistical parametric mapping software (SPM8; http://www.fi 
l.ion.ucl.ac.uk/spm) running in MATLAB version 7.14 (The Math Works Inc).   
 
Image preprocessing 
For each participant, the 100-volume functional time series were realigned to the first volume, 
corrected for motion artefacts, normalised to the Montreal Neurological Institute echo-planar imaging 
template, smoothed with an 8 mm full-width-at half-maximum Gaussian filter and band-pass filtered. 
 
Models and statistical inferences 
fMRI data were analysed using a two-stage random effects procedure (Friston et al. 1999). The first 
stage identified subject-specific task-related activations relevant to pattern trials (experimental 
condition) over the entire session as well as linear increases and decreases in activity over the 5 blocks 
of pattern trials. Random trials (control condition) served as the implicit baseline. The contrast images 
were obtained by using a boxcar design for each 30-s epoch convolved with the hemodynamic 
response function. Motion parameters obtained from the realignment pre-processing step were 
included as covariates at this stage. In the second stage of analysis, the resulting maps were used to 
establish task-related activations across subject-specific images using one-sample t-tests for each 
group (typical, atypical; risperidone, olanzapine) at baseline and follow-up. Significance was assessed 
with correction for multiple comparisons at the cluster level (p<0.01 corrected). The pattern > random 
contrast revealed insufficient activations at the corrected level in all analyses (thus not reported 
hereafter). Further described analyses were conducted on contrasts with linear increases and decreases 
in activity over the 5 blocks of pattern trials. Significant changes from baseline to follow-up in 
atypical antipsychotic group were examined with Group (typical, atypical) x Occasion (baseline, 
follow-up) SPM ANOVA, followed by paired t-tests separately in the typical and atypical groups. We 
further explored the regions that were significantly active at follow-up following a switch to 
risperidone or olanzapine (separately) using paired t-tests. Significance was assessed using a 
correction for multiple comparisons at the cluster level (p<0.05) with a height threshold of p=0.01 for 
baseline-to-follow-up activation changes in the typical and atypical groups, and p=0.05 (to 
accommodate smaller Ns and the exploratory nature of the analyses) in the risperidone and olanzapine 
subgroups.  
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Results 
Demographic and clinical measures 
Age, level of education, illness duration, age of onset and the dose of antipsychotic medication at 
baseline did not differ significantly between the typical and atypical antipsychotics group, or between 
the two atypical antipsychotic subgroups (risperidone, olanzapine) (Table 1). 
The change in symptom levels (from baseline to follow-up) was not significant for typical or 
atypical groups, or for either of the two atypical antipsychotic subgroups (Table 2; all p values >0.05 
for all Group, Occasion and Group x Occasion effects). 
 
****Table 2 about here**** 
 
Task performance 
The four-way repeated measures ANOVA (Group x Occasion x Trial type x Block) revealed a 
significant main effect of Block [F(4,84)=4.76, p =0.008, ηρ² =0.18] and a significant interaction 
between Occasion x Trial type [F(1,21)=6.84, p =0.02, ηρ²= 0.25]. The Group x Trial type x Occasion 
interaction failed to attain formal statistical significance (with small N/group) but it had a moderate 
effect size [F(1,21)=2.51, p=0.13, ηρ²=0.11], and the possible effects of typical and atypical 
antipsychotics on PL were explored to inform our hypotheses as noted below. 
The three-way repeated measures ANOVA (Group x Trial type x Block) on baseline data 
revealed non-significant effects involving Group, Trial type x Block [Trial type [F(1,21)=0.26, 
p=0.62, ηρ² =0.01; Block x Trial type; F(1,21)=0.04, p =0.85, ηρ² =0.002; Trial type x Group 
[F(1,21)=0.04, p=0.85, ηρ² = 0.002] confirming no difference between RTs to random and pattern 
trials during any of the blocks in typical or atypical antipsychotics groups at baseline (when all 
patients were on typical antipsychotics). There was only a main effect of Block [F(4,84)=3.60, 
p=0.03, ηρ²=0.15] with a linear effect [F(1,21)=5.52, p=0.029, ηρ² =0.21] indicating a reduction in 
RTs from block 1 to block 5 (of both random and pattern trials) across all patients at baseline (Table 
3).   
 The three-way repeated measures ANOVA (Group x Trial type x Block) on follow-up data 
showed a significant main effect of Trial type [F(1,21) =8.65, p=0.008, ηρ²=0.29] and importantly a 
significant Trial type x Group (typical, atypical) interaction [F(1,21)=5.77, p=0.03, ηρ²=0.22]. 
Separate analysis of typical and atypical group confirmed no effect of Trial type in the typical group 
[F(1,7)=0.17, p=0.70, ηρ²=0.02] but a strong main effect of Trial type in the atypical group 
[F(1,14)=17.53, p =0.001, ηρ²=0.56], showing faster RTs over pattern trials relative to random trials 
(Table 3; Figure 1). A significant main effect of Block [F(4,84)=2.95, p=0.05, ηρ²=0.12], with a linear 
decrease in RT over the 5 blocks of trials [F(1,21)=6.09, p=0.02, ηρ²=0.22], was also present but there 
was no significant interaction involving the Block factor (p >0.05). 
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The three-way repeated measures ANOVA (Occasion x Trial Type x Block) for the typical 
antipsychotic group yielded no significant effects of Trial type [F(1,7)=0.01, p=0.91 , ηρ²=0.002], 
Occasion [F(1,7)=1.14, p=0.32, ηρ²=0.14], or Occasion x Trial type [F(1,7)=0.29, p=0.61, ηρ²=0.04] 
indicating that patients who remained on typical antipsychotics did not show RT reduction to pattern 
trials relative to random trials at baseline or follow-up. The three-way repeated measures ANOVA 
(Occasion x Trial Type x Block) for the atypical group showed a significant main effect of Trial type 
[F(1,14)=5.30, p=0.04, ηρ²=0.27] and significant interaction effect of Occasion x Trial type 
[F(1,14)=6.08, p=0.001, ηρ²=0.53]. Follow-up of this (Occasion x Trial type) interaction showed no 
effect of Trial type or Block at baseline (p values >0.20) but a highly significant main effect of Trial 
type [F(1,14) = 17.54, p=0.001, ηρ²=0.56] showing much faster RTs during pattern trials than random 
trials over the entire experiment (random trials: mean=0.33 s, SEM=0.39; pattern trials: mean=0.298 
s, SEM=0.034) at follow-up in this group (Table 3).  
 Exploration of the atypical subgroups (risperidone, olanzapine) revealed comparable 
reduction in RTs to pattern trials relative to random trials at follow-up as demonstrated by a 
significant Occasion x Trial type interaction [F(1,13)=14.86, p=0.002, ηρ²=0.53], but no significant 
Group [F(1,13)=3.06, p=0.10, ηρ²=0.19], Group x Trial type [F(1,13)=0.58, p=0.46, ηρ² =0.04], or 
Group x Occasion x Trial type effect [F(1,13)=0.20, p =0.66, ηρ² =0.01]. 
 
****Table 3 and Figure 1 about here**** 
 
Age and illness duration did not correlate with PL scores at baseline (age: r=-0.12, p=0.58; illness 
duration: r=0.10, p=0.66) or follow-up (age: r=-0.03, p=0.88; illness duration: r=0.07, p=0.76). 
PANSS symptom ratings and PL scores were also not significantly correlated, at baseline (positive 
symptoms: r=-0.19, p=0.30; negative symptoms: r=-0.08, p=0.69; general psychopathology: r=-0.16, 
p=0.45; total symptoms: r=-0.04, p=0.85) or follow-up (positive symptoms: r=-0.09, p=0.68; negative 
symptoms: r=-0.14, p=0.52; general psychopathology: r=-0.19, p=0.39; total symptoms: r=-0.17, 
p=0.45). 
 
fMRI  
Generic task-related activations  
Baseline: In line with the behavioural results, there were no significant task-related activations in 
typical or atypical groups when patients were all on typical antipsychotics.  
 
Follow-up: Patients who remained on typical antipsychotics did not show any significant activation 
changes also at follow-up. In those who were switched to atypical antipsychotics, activity in the 
superior-middle frontal and anterior cingulate increased linearly over the five blocks of pattern trials 
(Table 4). When explored separately in the risperidone and olanzapine subgroups, the risperidone 
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subgroup showed significant activity increase over the five blocks in the lentiform nucleus extending 
to the insula (Table 4). The olanzapine subgroup showed significant activity increase over the five 
blocks in the caudate extending to the anterior cingulate and precentral gyrus (Table 4). No area 
showed activation decreases over the 5 blocks of pattern trials.  
 
****Table 4 about here**** 
 
Activation changes from baseline to follow-up 
There were no activation increases or decreases (at the corrected or uncorrected cluster level) from 
baseline to follow-up in those who remained on typical antipsychotics. Following a switch to atypical 
antipsychotics, increased activation, relative to baseline, was seen in one cluster in the bilateral 
superior frontal gyrus extending to the inferior frontal gyrus, and in another cluster in the left anterior 
cingulate, extending to the right putamen and bilateral caudate (Table 5, Figure 2A); no area showed a 
significant decrease in activity from baseline to follow-up. 
 
****Table 5 and Figure 2 about here**** 
 
During exploration of the two atypical groups separately, the risperidone group showed 
activation increases in a large cluster in the posterior cingulate, extending to the left middle occipital 
gyrus, bilateral paracentral lobule and left precuneus (Table 5). Additional activation increases, at the 
uncorrected cluster level, were found in the putamen (bilaterally) extending to the left caudate, 
bilateral insula and bilateral cingulate gyrus; the left superior temporal gyrus extending to the left 
inferior-middle frontal gyrus; the right middle temporal gyrus extending to the right parahippocampal 
gyrus; and the right superior frontal gyrus (Table 5, Figure 2B). In the olanzapine group, there was 
increased activity in bilateral anterior cingulate (bilateral), extending to the left precentral gyrus, right 
superior and bilateral middle frontal gyrus, left insula, bilateral caudate and left putamen (Table 5, 
Figure 2C). No area showed a significant decrease in activity from baseline to follow-up in the 
risperidone or olanzapine subgroups. 
 
Discussion  
To our knowledge, this is the first longitudinal fMRI study examining neural effects associated with 
switching schizophrenia patients from typical to atypical antipsychotics using a fMRI compatible PL 
task. We also explored the possible differentiation between risperidone and olanzapine.  
 
Behavioural findings 
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At baseline, patients (all patients on typical antipsychotics), did not show PL (i.e. no significant 
difference between RTs to random and pattern trials); there was also no difference in PL of patients 
who remained on typical antipsychotics and those who were later switched to receive risperidone or 
olanzapine. At follow-up, there was a difference between the typical and atypical groups that was in 
accordance with our a priori hypotheses, with significantly faster RTs to pattern, relative to random 
trials, in those on atypical (but not typical) antipsychotics.  
An aspect of the experiment deserving comment is that although significantly faster RTs to 
pattern, relative to random trials, reflects PL in the atypical group at follow-up, this difference was 
present even during the very first block of trials, suggesting that patients on atypical antipsychotics 
had learnt the sequence during the first block itself perhaps due to the practice session conducted just 
prior to scanning. This was also observed earlier in a healthy group with the same task and 
administration procedures (Kumari et al. 2002) but it may also mean that the neural findings of this 
study relate to the recall, rather than acquisition, of implicit knowledge about the sequences. 
The pattern of results obtained in the typical and atypical antipsychotic groups at baseline and 
follow-up is consistent with the finding of previous studies using SRTT (Green et al. 1997; Kumari et 
al. 2008; Kumari et al. 2002), and also of those using other PL tasks (Paquet et al. 2004; Purdon et al. 
2003; Scherer et al. 2004). Specifically, studies have reported normal PL on a visual tracking task in 
patients on olanzapine, but not in those on haloperidol (Paquet et al. 2004); normal PL on a mirror 
drawing task in those on clozapine or risperidone, but not in those on haloperidol (Scherer et al. 2004) 
and preserved PL, defined as the improvement observed between two blocks of five trials of the 
Tower of Toronto, following 6 months of treatment with olanzapine but a decline following the 6 
month use of risperidone or typical antipsychotics in medication-naïve patients (Purdon et al. 2003). 
Atypical antipsychotic treatment related PL changes apparent at follow-up may at least in part 
represent a functional consequence of the robust antagonism of D2 receptors in the striatum by typical 
antipsychotics at baseline (Bedard et al. 1996; Kumari et al. 2002), and less so at follow-up. The 
inconsistency of results in previous studies regarding risperidone use may be explained by varying 
doses of risperidone and sample characteristics in previous studies. Risperidone when given at doses 
of more than 8 mg/daily produces an extrapyramidal symptoms profile (Lemmens et al. 1999) and D2 
blockade broadly similar to that of typical antipsychotics (Marder and Meibach 1994). The effects of 
risperidone at a given dose are also known to be affected by illness chronicity. Maximum 
antipsychotic activity occurs at 4-6 mg/day for chronic schizophrenia patients whereas first episode 
patients respond to lower (2-5mg/day) doses, and in chronic patients daily doses of up to 8 mg/day are 
not associated with a greater risk of extrapyramidal symptoms than placebo (Foster and Goa, 1998). 
The patients included in our study were chronically ill, and no patient was on more than 8 mg daily 
dose of risperidone (6/8 patients on 4-6 mg/day). This may explain improved PL in risperidone-
treated patients at follow-up in our study.  
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Previously, it has been suggested that PL deficits may be linked to symptomatic state (Exner 
et al. 2006). However, absent PL in the typical antipsychotic group does not seem to be related to 
clinical manifestation of symptoms or attentional difficulties since their RTs improved over 
successive blocks. It is likely that task familiarity or practice contributed to RT learning in typical 
antipsychotic patients since faster RT over blocks 1 to 5 occurred only at follow-up. Patients on 
typical antipsychotics have been suggested to rely on RT learning whilst healthy controls tend to 
switch from RT learning to pattern learning towards later trials (Green et al. 1997). Improved PL 
despite non-significant symptom changes at follow-up in patients who were switched to atypical 
antipsychotics also suggests lack of a direct relationship between PL and symptom levels in stable 
schizophrenia patients.    
 
Neural changes following a switch to atypical antipsychotics  
Typical antipsychotics use was associated with deficient task-related activation at baseline and 
follow-up. This complements our behavioural results of absent PL and replicates a previous fMRI 
study involving male patients only (Kumari et al. 2002). As anticipated, six week atypical 
antipsychotic treatment was associated with increased activation (over the five successive blocks of 
pattern trials) in the superior frontal gyrus extending to the inferior frontal gyrus, and anterior 
cingulate extending to the caudate and putamen. Importantly, the areas showing activation increases 
following atypical antipsychotic treatment closely resemble those shown by healthy controls (Kumari 
et al. 2008; Purdon et al. 2011; Reiss et al. 2006; Zedkova et al. 2006). It is thus possible that the lack 
of PL and the lack of task-related activations at baseline were due, at least in part, to the potent D2 
blocking mechanism of typical antipsychotics as suggested previously (Bedard et al. 1996; Kumari et 
al. 1997; Kumari et al. 2002). Interestingly, increased activation in the superior-inferior frontal gyrus, 
anterior cingulate and striatum was present as a linear increase over five successive 30-s blocks of 
sequenced trials. This observation, taken together with an earlier finding showing that clozapine-
treated patients show progressive PL over successive trials whereas those treated with haloperidol 
show a high degree of fluctuation over trials (Bedard et al. 1996), indicates that a linear contrast may 
be more useful in characterising the incapacity to automate pattern learning in typically-treated 
patients or a better capacity to reach optimal performance over a 5 minute period in atypically-treated 
patients. 
 
Exploration of neural changes following a switch to risperidone and olanzapine 
When baseline-to-follow-up neural changes were explored separately in the two atypical subgroups, 
partially overlapping and idiosyncratic activation changes emerged. Despite equivalent behavioural 
performance, the risperidone group activated regions in the posterior cingulate extending to middle 
occipital gyrus, paracentral lobule and precuneus followed by non-significant activation changes in 
the putamen, caudate, insula, cingulate gyrus, temporal regions and superior frontal gyrus. Increased 
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activity in the posterior cingulate and middle temporal gyrus [in ziprasidone treated individuals 
(Kumari et al. 2008)] and the precuneus [in healthy controls (Kumari et al. 2002)] has been shown to 
have direct positive association with PL magnitude. Temporal regions have been suggested to play a 
compensatory role to overcome fronto-striatal deficits in schizophrenia and thereby achieve 
comparable PL as healthy controls (Zedkova et al. 2006). The risperidone treated group failed to 
activate striatal regions at the corrected level (possibly due to higher D2 blocking properties of 
risperidone, compared to olanzapine), further supporting that compensatory action of alternate regions 
contributed to the observation of improved PL at follow-up in this group. 
Following a switch to olanzapine significant task-related activation changes were detected in 
the anterior cingulate extending to the precentral gyrus, superior frontal gyrus, middle frontal gyrus, 
insula and striatum. Activation of this neural network is consistent with previous studies following 
successful PL in healthy controls (Kumari et al. 2008; Kumari et al. 2002; Purdon et al. 2011; 
Zedkova et al. 2006). This focused activation of PL-related regions possibly contributed to PL 
normalising effects of olanzapine.  
 
Limitations 
First, this study is limited by unequal groups and small sample size and subsequent lack of robust 
statistical power. However, switching the same patients from typical to atypical antipsychotics 
reduced inter-individual differences. A second limitation may be the inclusion of patients on a range 
of oral and depot typical antipsychotics, introducing a potential source of heterogeneity. Previous 
studies have suggested that various typical antipsychotics may have differential neural and cognitive 
effects depending on their potency (Abbott et al. 2011; Keefe et al. 2007a). Future studies could 
include low-potency typical antipsychotics when comparing with atypical antipsychotics. Thirdly, the 
duration of exposure to atypical antipsychotics was short. Since PL has been shown to decline after 6 
months treatment with risperidone but not with olanzapine (Purdon et al. 2003), longer-term follow-
up is needed for medication to be stabilised and to help elucidate how medication induced changes in 
neural function evolve over time. Fourthly, this study, as also mentioned earlier, may have identified 
neural effects associated with recall, and not acquisition, of implicit knowledge about the sequences. 
Further research with more sophisticated analytic strategies and longer exposures (e.g., with inclusion 
of the practice session and repeated presentation of the task) is required to explore this possibility. 
Practice session data in all baseline and follow-up sessions were not systematically recorded, thus the 
exact effects of the practice session on baseline or follow-up task performance could not be examined 
in the present study. Further research could also use different experimental designs to separate the RT 
(fine motor) and sequence learning (cognitive) components, the latter of which is more likely to 
involve higher cortical brain regions, and include an additional group of treatment-naïve 
schizophrenia patients to clarify the effects of typical antipsychotics on PL and related brain 
activations. Fifthly, given the dose-dependent actions of atypical antipsychotics on dopamine D2 
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receptors and in addition on many other receptors (Arnt and Skarsfeldt, 1998; Foster and Goa, 1998), 
and the absence of receptor imaging data in this study, our suggestion of reduced antagonism of D2 
receptors at follow-up (relative to baseline) in those switched to risperidone or olanzapine as the 
potential mechanism for improved PL seen in this study remains speculative and requires further 
study. Finally, although not directly relevant to the aims of this study, it would have been informative 
to study a matched healthy control group over two occasions and establish healthy activation patterns 
in a test retest design.  
 
Conclusions 
Our finding of absent PL and deficient task-related activation at baseline and follow-up in the typical 
antipsychotic group and normalisation of PL and restoration of PL-related regions following a switch 
to atypical antipsychotics suggest that PL deficits may be secondary to treatment with typical 
antipsychotics via potent D2 blocking mechanism. Substituting risperidone and olanzapine may have 
different effects on brain function and this in turn may relate to the differences in their receptor 
binding long term clinical profiles. The present findings suggest that SRTT combined with fMRI may 
provide a useful biomarker for exploring the effects of medication on PL and emphasise the 
importance of considering medication status and antipsychotic type in neuroimaging studies. 
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Table 1. Descriptive statistics [mean, standard deviation (SD)] and analysis of variance (ANOVA) results for demographics and clinical characteristics of 
patient groups and subgroups. 
 
  Typical 
(n = 8; 5 men) 
Atypical 
(n = 15; 9 men) 
ANOVA Atypical subgroups ANOVA 
Group Effect Risperidone  
(n = 7; 5 men) 
Olanzapine  
(n = 8; 4 men) 
Group Effect 
  Mean (SD) Mean (SD) F(1,21) p Mean (SD) Mean (SD) F(1,13) p 
Age (years) 46.00 (9.81) 38.60 (15.28) 1.52 0.22 35.57 (13.73) 41.25 (16.97) 0.50 0.49 
Education (years) 11.25 (3.69) 12.73 (3.61) 0.87 0.36 12.29 (3.30) 13.13 (4.05) 0.19 0.67 
Predicted (NART) IQ 96.37 (16.31) 103.33 (14.39) 1.11 0.30 100.57 (16.35) 105.75 (13.06) 0.47 .51 
Age at illness onset (years) 23.43 (5.62) 25.13 (10.66) 0.16 0.70 20.71 (3.90) 29.00 (13.33) 2.46 0.14 
Duration of illness (years) 20.43 (9.88) 13.47 (12.75) 1.61 0.22 14.86 (14.75) 12.25 (11.63) 0.15 0.71 
Antipsychotic dose in 
chlorpromazine equivalents (mg) 
220.84 (146.04) 
 
 
*267.86 (251.62) 
 
*
10.23 0.64 314.29 
(337.53) 
*221.43 (134.96) *20.46 0.51 
*Dose information missing for one patient, *1df=1,20. *2df=1,12.  
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Table 2. Descriptive statistics [mean, standard deviation (SD)] and analysis of variance (ANOVA) results for symptom measures and task performance at 
baseline and follow-up.  
 Typical (n = 8) Atypical (n = 15) ANOVA 
 Baseline Follow-up Baseline Follow-up Group 
 
Occasion 
 
Group x Occasion 
 
aPANSS Symptoms Mean (SD) Mean (SD) Mean (SD) Mean (SD) F (1,21),  p F(1,21) p F (1,21) p 
Positive symptoms 14.75 (6.02) 13.62 (6.43) 19.07 (6.66) 15.86 (5.05) 1.93 0.18 3.37 0.08 0.77 0.39 
Negative symptoms 17.37 (4.17) 15.25 (5.55) 19.47 (6.44) 18.80 (6.74) 1.34 0.26 1.68 0.21 0.46 0.50 
General Psychopathology 36.37 (9.16) 33.87 (9.55) 40.40 (10.04) 35.67 (9.64) 0.61 0.44 3.16 0.09 0.30 0.59 
Total symptoms 68.50 (16.13) 62.75 (18.52) 78.93 (20.23) 70.33 (19.51) 1.46 0.24 3.59 0.07 0.14 0.71 
Separately for risperidone and olanzapine groups       
 Risperidone (n =7) Olanzapine (n=8) ANOVA 
 Baseline Follow-up Baseline Follow-up Group Occasion Group x Occasion 
 
aPANSS Symptoms Mean (SD) Mean (SD) Mean (SD) Mean (SD) F (1,13),  p F(1,13) p F (1,13) p 
Positive symptoms 18.29 (8.36) 13.86 (4.49) 19.75 (5.26) 17.62 (5.12) 1.05 0.33 3.87 0.07 0.48 0.50 
Negative symptoms 18.57 (6.24) 19.14 (7.69) 20.25 (6.94) 18.50 (6.32) 0.02 0.88 0.20 0.66 0.79 0.39 
General Psychopathology 39.57 (9.96) 34.29 (10.37) 41.12 (10.74) 36.87 (9.51) 0.22 0.64 2.74 0.12 0.03 0.86 
Total symptoms 76.43 (22.01) 67.29 (21.65) 81.12 (19.79) 73.00 (18.50) 0.01 0.92 2.70 0.12 0.01 0.92 
aPositive and Negative Syndrome Scale (PANSS; Kay et al. 1987).
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Table 3. Task performance [mean, standard error of the mean (SEM)] of patient groups and sub-
groups at baseline and follow-up.  
 Typical (n = 8)  Atypical (n = 15) 
Task performance Baseline Follow-up  Baseline Follow-up 
Reaction time (ms) Mean (SEM) Mean (SEM)  Mean (SEM) Mean (SEM) 
Block 1 
Random Trials 0.348 (0.075) 0.308 (0.063)  0.296 (0.055) 0.338 (0.0465) 
Pattern Trials 0.426 (0.089) 0.314 (0.056)  0.322 (0.065) 0.301 (0.041) 
Block 2 
Random Trials 0.433 (0.085) 0.302 (0.055)  0.353 (0.062) 0.335 (0.040) 
Pattern Trials 0.447 (0.075) 0.303 (0.059)  0.308(0.055) 0.318(0.043) 
Block 3 
Random Trials 0.430 (0.077) 0.292 (0.062)  0.319 (0.056) 0.343 (0.046) 
Pattern Trials 0.469 (0.091) 0.286 (0.052)  0.330 (0.067) 0.301 (0.038) 
Block 4 
Random Trials 0.466 (0.081) 0.295 (0.052)  0.302 (0.059) 0.317 (0.038) 
Pattern Trials 0.448 (0.083) 0.296 (0.051)  0.314 (0.061) 0.288 (0.037) 
Block 5 
Random Trials 0.393 (0.068) 0.267 (0.048)  0.294 (0.049) 0.316 (0.035) 
Pattern Trials 0.395 (0.076) 0.270 (0.047)  0.303 (0.056) 0.282 (0.0346) 
Separately for risperidone and olanzapine groups  
 
Risperidone (n =7)  Olanzapine (n=8) 
Baseline Follow-up  Baseline Follow-up 
Reaction time (ms) Mean (SEM) Mean (SEM)  Mean (SEM) Mean (SEM) 
Block 1 
Random Trials 0.230 (0.025) 0.322 (0.082)  0.355 (0.072) 0.352 (0.059) 
Pattern Trials 0.223 (0.017) 0.278 (0.052)  0.408 (0.099) 0.321 (0.055) 
Block 2 
Random Trials 0.232 (0.026) 0.305 (0.058)  0.459 (0.094) 0.361 (0.055) 
Pattern Trials 0.218 (0.020) 0.296 (0.075)  0.387 (0.066) 0.337 (0.048) 
Block 3 
Random Trials 0.218 (0.033) 0.339 (0.010)  0.407 (0.070) 0.347 (0.035) 
Pattern Trials 0.206 (0.027) 0.290 (0.070)  0.438 (0.082) 0.310 (0.036) 
Block 4 
Random Trials 0.192 (0.032) 0.283 (0.059)  0.399 (0.061) 0.347 (0.037) 
Pattern Trials 0.197 (0.024) 0.256 (0.054)  0.416 (0.068) 0.317 (0.039) 
Block 5 
Random Trials 0.194 (0.036) 0.300 (0.060)  0.381 (0.054) 0.330 (0.032) 
Pattern Trials 0.197 (0.029) 0.254 (0.036)  0.395 (0.058) 0.307 (0.034) 
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Table 4. Brain areas showing significant activation increases (over block 1 to block 5 of pattern, 
relative to random, trials) in the atypical antipsychotics group at follow-up. 
 
Brain Region BA Side MNI coordinates  Voxel 
T 
value 
Cluster 
size 
(Voxel n) 
Cluster  
Corrected p 
x y z 
Atypical antipsychotics (across risperidone and olanzapine) (height threshold p= 0.01) 
Superior frontal gyrus  10 R 36 58 2 4.91 1259 0.016 
10 R 24 60 6 3.41 
10 R 24 52 16 3.10 
Middle frontal gyrus 10/46 R 34 56 16 3.68 
Anterior cingulate 
/medial frontal gyrus 
32/10 R 2 54 14 3.46 
Separately for risperidone and olanzapine (height threshold p= 0.05) 
Risperidone 
Lentiforn nucleus n/a R 24 -20 -4 7.75 4496 0.001 
Insula n/a R 34 24 8 7.23 
Superior frontal gyrus 10 R 32 48 -2 3.48   
Olanzapine 
Caudate n/a R 6 2 10 4.97 5879 0.01 
Anterior cingulate 24/32 R 12 32 20 4.66 
Precentral gyrus 6 R 36 -2 28 4.49 
BA: Brodmann area. MNI = Montreal Neurological Institute. R=right; L=left.  
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Table 5. Brain areas showing significant activation increases (over block 1 to block 5 of pattern, 
relative to random, trials) from baseline to follow-up after a switch to atypical antipsychotics (height 
threshold p= 0.01). 
Brain Region BA Side MNI coordinates  Voxel T 
value 
Cluster 
size 
(Voxel n) 
Cluster p 
 
x y z 
Following a switch to atypical antipsychotics risperidone or olanzapine (height threshold p=0.01) 
Superior frontal gyrus  
 
10 R 20 50 18 4.26 1115 0.007 
10 L -22 50 6 3.39 
Inferior frontal gyrus 
 
47 R 30 34 4 3.56 
10 L -40 52 6 3.27 
Anterior cingulate 32 L -14 18 22 4.6 851 0.029 
Putamen   R 22 4 8 3.67 
Caudate 
 
 R 14 26 8 3.21 
 L -16 6 14 3.07 
Separately for risperidone and olanzapine (height threshold p = 0.05) 
Following switch to risperidone    
Posterior cingulate 
 
30 L -16 -60 4 11.31 6037 < 0.001 
30 R 10 -58 18 6.14 
Middle occipital gyrus  19 L -22 -68 4 7.72 
Paracentral lobule 
 
5 R 18 -40 54 7.14 
5 L -6 -44 48 6.80 
Precuneus 19 L -32 -78 38 6.69 
Putamen  
 
n/a L -16 6 10 10.35 2029 0.002 
n/a R 32 4 10 5.83 
Caudate n/a L -12 12 2 5.68 
 Insula  n/a L -34 -12 8 5.37 
Cingulate gyrus  
     
24 R 4 -10 26 5.17 
24 L -2 -6 28 3.87 
Anterior cingulate 32 L -2 12 26 4.24 
Superior temporal gyrus  22 L -48 -16 -8 9.89 
1097 
0.018 
Inferior frontal gyrus  47 L -46 24 0 9.73 
Middle frontal gyrus  9 L -30 30 22 6.75 
Middle temporal gyrus  21 R 54 -18 -16 9.91 
1033 
0.021 
Parahippocampal gyrus 36 R 46 -32 -10 5.85 
Superior frontal gyrus 10 R 18 66 18 6.12 811 0.037 
Following switch to olanzapine  
Anterior cingulate  
 
32 L -14 18 22 3.84 7429 
  
< 0.001 
  32 R 12 18 22 3.55 
Precentral gyrus  6 L -36 -2 28 3.55 
Cingulate gyrus 32 R 18 4 46 3.48 
Superior frontal gyrus 6 R 2 6 58 3.45 
Middle frontal gyrus  
     
9 R 38 28 42 3.43 
8 L -26 30 52 3.43 
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Insula 13 L -46 -2 16 3.41 
Caudate 
    
 L -6 4 20 3.37 
 R 4 6 8 3.37 
Putamen  L -18 18 2 3.3 
BA: Brodmann area. MNI = Montreal Neurological Institute. R=right; L=left; Cluster P in italics: 
uncorrected. All others: cluster p corrected for multiple comparisons across the entire brain.   
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Figure1. A: Mean (+1 standard error of the mean) procedural learning scores (mean reaction times 
over 5 blocks of pattern trials minus mean reaction times over 5 blocks of random trials) at baseline 
and follow-up in the group that remained on typical antipsychotics and the group that was switched to 
atypical antipsychotics (risperidone or olanzapine). B: Mean (+1 standard error of the mean) 
procedural learning scores at baseline and follow-up in patients switched from typical antipsychotics 
to risperidone and olanzapine. 
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Figure 2. A. Areas of increased brain activity following atypical antipsychotic treatment (height 
threshold p < 0.01) in axial views with associated MNI z co-ordinates. Left hemisphere is shown on 
the left. B and C. Areas of increased brain activity separately for atypical antipsychotic subgroups – 
risperidone and olanzapine (height threshold p <0.05).  
 
 
